Multimodal TRAIL Agents in Encapsulated Stem Cells for Glioblastoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for glioblastoma, face challenges in achieving sustained and localized delivery of therapeutic agents, leading to minimal anti-tumor effects due to rapid clearance and off-target binding, limiting the effectiveness of systemic administration and direct infusion methods.
Innovation Solution
Development of multimodal TRAIL agents comprising a therapeutic TRAIL module and a reporter module, engineered into stem cells encapsulated in biodegradable synthetic extracellular matrix, allowing for sustained, localized delivery and real-time monitoring, which enables targeted apoptosis of tumor cells while minimizing harm to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If systemic administration or direct infusion of TRAIL agents is used, then therapeutic coverage is achieved, but delivery duration is shortened due to rapid clearance and off-target binding
Solution Approach 1:
The patent uses engineered stem cells as intermediary carriers that naturally migrate to tumor sites. These stem cells express TRAIL agents and reporter modules, serving as living factories that deliver therapy locally while avoiding systemic circulation issues. The stem cell tropism for tumors provides targeted delivery without requiring direct infusion or systemic administration.
Solution Approach 2:
The stem cells autonomously navigate to tumor sites using their natural migratory properties. Once at the tumor, they continuously produce and secrete TRAIL agents locally. This self-directed approach eliminates the need for external pumping or repeated infusions, providing sustained delivery through the cells' inherent biological functions.
2Duration of action of moving object
If engineered stem cells encapsulated in biodegradable synthetic extracellular matrix are used, then localized delivery and sustained release are achieved, but device complexity increases
Solution Approach 1:
The patent employs biodegradable synthetic extracellular matrix materials whose degradation rate can be tuned to match the therapeutic release profile. By controlling the degradation parameters of the matrix, sustained release is achieved without requiring complex mechanical structures. The matrix gradually breaks down, releasing stem cells and TRAIL agents over time.
Solution Approach 2:
The system combines biodegradable synthetic extracellular matrix with living stem cells to create a composite delivery system. The matrix provides structural support and controlled degradation, while the stem cells provide active therapy production and migration capability. This composite approach achieves sustained localized delivery through material properties rather than mechanical complexity.
3Measurement precision
If multimodal TRAIL agents with reporter modules are used, then real-time monitoring capability is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent merges the therapeutic TRAIL function with diagnostic reporter module functions into a single multimodal agent expressed by the stem cells. This consolidation allows simultaneous therapy and monitoring without requiring separate administration of multiple agents. The reporter modules (e.g., luciferase, fluorescent proteins) are co-expressed with TRAIL in the same stem cell population.
Solution Approach 2:
The engineered stem cells serve multiple functions: they migrate to tumors, produce TRAIL agents for therapy, and express reporter modules for imaging and monitoring. This multi-functionality is achieved through genetic engineering of the stem cells to co-express multiple proteins, simplifying the overall system compared to using separate therapeutic and diagnostic agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach demonstrates increased survival in mouse models by ensuring continuous, localized delivery of TRAIL agents to tumors, delaying tumor regrowth and improving survival rates, while minimizing systemic toxicity and off-target effects.
Implementation Method 1
These novel multimodal TRAIL agents are easily optically visualized for serial monitoring of cell-based pharmacokinetics
Data Source
AI summary
Described herein are novel compositions comprising multimodal TRAIL agents and cells engineered to express such multimodal TRAIL agents, including cells encapsulated in a scaffold or matrix, for use in the treatment of disorders such as cancer.